These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35167860)

  • 1. Managing Pulmonary Infection in Adults With Cystic Fibrosis: Adult Cystic Fibrosis Series.
    Green HD; Jones AM
    Chest; 2022 Jul; 162(1):66-75. PubMed ID: 35167860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.
    Govan JR; Brown AR; Jones AM
    Future Microbiol; 2007 Apr; 2(2):153-64. PubMed ID: 17661652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis.
    Ramsay KA; Sandhu H; Geake JB; Ballard E; O'Rourke P; Wainwright CE; Reid DW; Kidd TJ; Bell SC
    J Cyst Fibros; 2017 Jan; 16(1):70-77. PubMed ID: 27515017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy?
    Horsley A; Webb K; Bright-Thomas R; Govan J; Jones A
    Front Cell Infect Microbiol; 2011; 1():18. PubMed ID: 22919584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.
    Chmiel JF; Aksamit TR; Chotirmall SH; Dasenbrook EC; Elborn JS; LiPuma JJ; Ranganathan SC; Waters VJ; Ratjen FA
    Ann Am Thorac Soc; 2014 Sep; 11(7):1120-9. PubMed ID: 25102221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology and management of pulmonary infections in cystic fibrosis.
    Gibson RL; Burns JL; Ramsey BW
    Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.
    Horsley A; Jones AM
    Cochrane Database Syst Rev; 2012 Oct; 10():CD009529. PubMed ID: 23076960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center.
    Campana S; Taccetti G; Ravenni N; Masi I; Audino S; Sisi B; Repetto T; Döring G; de Martino M
    J Cyst Fibros; 2004 Aug; 3(3):159-63. PubMed ID: 15463902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.
    Horsley A; Jones AM; Lord R
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD009529. PubMed ID: 26789750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.
    Razvi S; Quittell L; Sewall A; Quinton H; Marshall B; Saiman L
    Chest; 2009 Dec; 136(6):1554-1560. PubMed ID: 19505987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection.
    Martina P; Feliziani S; Juan C; Bettiol M; Gatti B; Yantorno O; Smania AM; Oliver A; Bosch A
    Int J Med Microbiol; 2014 Nov; 304(8):1182-91. PubMed ID: 25217078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which pathogens should we worry about?
    Jones AM
    Paediatr Respir Rev; 2019 Aug; 31():15-17. PubMed ID: 30967346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel antibiotic combinations proposed for treatment of
    El-Halfawy OM; Naguib MM; Valvano MA
    Antimicrob Resist Infect Control; 2017; 6():120. PubMed ID: 29204272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis.
    Shreve MR; Butler S; Kaplowitz HJ; Rabin HR; Stokes D; Light M; Regelmann WE
    J Clin Microbiol; 1999 Mar; 37(3):753-7. PubMed ID: 9986845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aetiological agents for pulmonary exacerbations in children with cystic fibrosis: An observational study from a tertiary care centre in northern India.
    Arvind B; Medigeshi GR; Kapil A; Xess I; Singh U; Lodha R; Kabra SK
    Indian J Med Res; 2020 Jan; 151(1):65-70. PubMed ID: 32134016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.
    Conway SP; Brownlee KG; Denton M; Peckham DG
    Am J Respir Med; 2003; 2(4):321-32. PubMed ID: 14719998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Isolation frequency of Burkholderia cepacia from cystic fibrosis patients].
    Ocak F; Gözalan A; Ozçelik U; Anadol D; Kiper N; Aktepe OC; Göçmen A; Esen B
    Mikrobiyol Bul; 2002 Jan; 36(1):1-10. PubMed ID: 12476760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis.
    Psoter KJ; De Roos AJ; Wakefield J; Mayer JD; Rosenfeld M
    BMC Infect Dis; 2017 Jun; 17(1):411. PubMed ID: 28599639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Microbiological diagnosis of bronchopulmonary colonization-infection in cystic fibrosis].
    Oliver A; Alarcón T; Caballero E; Cantón R
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):89-104. PubMed ID: 19232782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.